What factors drove the changes in COMPASS Pathways's revenue and profit?

What does COMPASS Pathways do and what are its main business segments?

What were the key takeaways from COMPASS Pathways’s earnings call?

What guidance did COMPASS Pathways's management provide for the next earnings period?

What were the key takeaways from COMPASS Pathways's earnings call?

Did COMPASS Pathways beat or miss consensus estimates last quarter?

What is COMPASS Pathways's latest dividend and current dividend yield?

What is COMPASS Pathways's gross profit margin?

- **9-12 Month Launch Acceleration**: FDA-supported rolling NDA submission and completed Phase III enrollment drive 9-12 month timeline reduction.
- **Commercial Readiness**: 6,000+ SPRAVATO-capable sites primed for COMP360, with REMS mirroring SPRAVATO protocols.
- **Financial Stability**: $186M cash on hand, maintaining runway to 2027; Q3 cash used: $35M, full-year guidance: $120-145M.
- **PTSD Trial Progress**: Protocol finalized, targeting Q1 2026 first patient enrollment.

**【CEO Summary Section】**
- **Accelerated Launch Timeline**: 9-12 month acceleration due to Phase III trial enrollment completion and FDA support for rolling NDA submission. 006 trial enrollment completed ahead of schedule, with 26-week data expected in Q3 2026.
- **FDA Interaction**: Positive dialogue with FDA on filing strategy, including potential rolling submission. 9-week data from 006 and 26-week data from 005 to be disclosed in Q1 2026.
- **Commercial Readiness**: Pulling forward commercial activities, leveraging insights from 6,000+ SPRAVATO-capable sites. Sites administering SPRAVATO are expected to easily transition to COMP360 if approved.
- **PTSD Trial Progress**: Protocol finalized for PTSD trial, with potential first patient enrollment in Q1 2026.

**【CFO Financial Commentary】**
- **Cash Position**: $186 million as of Q3 2025, maintaining cash runway to 2027. Q3 cash used in operations: $35 million; full-year guidance: $120-145 million.
- **Regulatory & Commercial Investment**: Added resources to regulatory team for NDA preparation and accelerated commercial activities. Debt under Hercules loan facility: $31.3 million.

**【Q&A Key Highlights】**
- **FDA & REMS Requirements**: FDA supportive of rolling submission; REMS likely to mirror SPRAVATO, allowing single or group administration based on clinician comfort.
- **Commercial Partner Selection**: No partner selected yet; focus on aligning with existing SPRAVATO infrastructure.
- **Durability & Efficacy**: 26-week data from 005 (single dose) and 006 (2 doses) to demonstrate durability, with potential for one-time administration efficacy.
- **VA Engagement**: VA's integrated project team actively planning for psychedelic treatment implementation post-approval.

COMPASS Pathways plc (CMPS) Q3 2025 Earnings Call Transcript

- **Breakthrough Depression Data**: COMP360 achieved 3.6-point reduction vs. placebo at 6 weeks (single dose), matching SPRAVATO's 8-dose efficacy.
- **FDA Fast Track Potential**: Submitted for National Priority Review Voucher; Q3 meeting to explore accelerated approval.
- **Commercial Readiness**: 6,000+ clinics with SPRAVATO infrastructure can administer COMP360.
- **Financial Strength**: $222M cash runway into 2027; $120-145M annual spending guidance.
- **Expanded Indications**: PTSD trial design finalizing; anorexia Phase II showed efficacy signals.

**【Management Opening Remarks】**
- **Board Updates**: Welcome Justin Gover (former GW Pharmaceuticals CEO) to the Board; Linda McGoldrick to retire after 5 years of service.
- **COMP360 005 Trial Success**: Achieved primary endpoint with 3.6-point difference vs. placebo (clinically meaningful >3 points), statistically significant at 6 weeks with single administration. Results comparable to SPRAVATO's 8-dose regimen.
- **TRD Milestone**: 2/2 late-stage studies positive, treating 230+ hard-to-treat patients.
- **Commercial Prep**: Engaging mental health providers; COMP360's 4-hour admin vs. SPRAVATO's 3-hour clinic visit may reduce caregiver burden.
- **Expanded Indications**: PTSD late-stage trial design nearing completion; anorexia Phase II showed efficacy signals (reduced eating disorder/depressive symptoms), though limited by small sample size.

**【CFO Financial Commentary】**
- **Cash Position**: $222M (Q2 2025) vs. $260M (Q1 2025), funding operations into 2027.
- **Operational Spending**: Q2 cash used: $38.7M; full year guidance: $120-145M.
- **Debt**: $30.9M under Hercules loan facility.
- **Strategic Focus**: Finalizing PTSD trial design; preparing for potential 2026 launch.

**【Q&A Highlights】**
- **FDA Engagement**: Submitted application for Commissioner's National Priority Review Voucher; meeting scheduled for Q3 to discuss accelerated path. Agency feedback positive on 2/2 late-stage success.
- **Enrollment Momentum**: 006 trial recruitment strong post-005 results; 26-week data expected H2 2026.
- **Commercial Infrastructure**: 6,000+ SPRAVATO centers have single-room setup compatible with COMP360; CPT code reimbursement covers psychedelic therapy.
- **Safety Profile**: No suicidality imbalance in 005/006; anorexia study showed higher suicidality rates (illness-driven), but no drug-related safety signals.
- **Regulatory Strategy**: May submit NDA with 005 data alone if FDA agrees; 006 data to follow if needed.

COMPASS Pathways plc (CMPS) Q2 2025 Earnings Call Transcript

- **Clinical Milestone**: Phase 3 trial Part A dosing complete; 6-week results expected June 2025 with focus on MADRS efficacy metrics.
- **Durability Evidence**: 52-week follow-up shows 12-week average time to relapse, with 189 days for highly responsive subgroup.
- **Financial Strength**: $260M cash runway supports operations through 2026; manufacturing expansion plans underway.
- **Key Risk**: Suicidality monitoring continues; no FDA concerns over trial design despite historical data challenges.

**【CEO Key Updates】**
- **Phase 3 Trial Milestone**: All participants in Part A of the 005 trial (first pivotal Phase 3) have completed dosing. Top-line 6-week results expected in late June, focusing on MADRS score difference, p-value, and confidence interval.
- **Durability Data**: 52-week follow-up from Phase 2b showed average time to depressive event of 12 weeks for all patients, and 189 days for a subgroup of 58 patients who continued treatment. This highlights potential long-term benefits of the 25mg dose.
- **Commercialization Strategy**: Collaborations with providers like HealthPort aim to ensure equitable access, particularly in underserved communities. Focus on understanding delivery models and scaling post-approval.

**【CFO Financial Highlights】**
- **Cash Position**: $260M as of Q1 2025, sufficient to fund operations through the 26-week readout of the 006 trial (H2 2026). Cash used in operations for Q1: $45.7M; full-year guidance: $120-145M.
- **Manufacturing Plans**: UK-based production with plans to add US manufacturing sites ahead of potential commercialization. Process is straightforward, reducing supply chain risks.

**【Q&A Key Takeaways】**
- **Suicidality Monitoring**: DSMB reviewing safety data unblinded but trial remains blinded until 26 weeks. No significant suicidality imbalance noted to date; FDA not raising concerns about suicidality in Phase 3 design.
- **Placebo Effect Expectations**: Anticipate MADRS placebo response of ~3 points, with clinically significant effect defined as >3 points difference.
- **Competitor Comparisons**: Emphasize unique paradigm-shifting potential of COMP360 vs. existing treatments like esketamine, with focus on standalone efficacy rather than combination therapies.
- **Regulatory Pathway**: No changes in FDA interactions; ongoing discussions on PTSD program design but no public updates yet.

COMPASS Pathways (CMPS)-8 May 25-2025 Q1 Earnings call transcript

- **Upcoming Data Milestones**: 6-week COMP005 results in Q2 2025 and 26-week COMP006 data in H2 2026. 
- **PTSD Program Restart**: $140M financing enables late-stage development for unmet need in PTSD. 
- **Financial Strength**: $305M cash runway supports clinical progress through 2026. 
- **Strategic Differentiation**: COMP360's rapid-acting, single-dose profile addresses TRD and PTSD gaps. 


**【CEO Summary Section】**
- **Phase 3 Trial Progress**: COMP005 trial is 90% enrolled, with top-line 6-week MADRS results expected in Q2 2025. COMP006 trial is on track for 26-week data in H2 2026. 
- **PTSD Development Update**: $140M financing enables resumption of COMP360 PTSD program, with clinical design discussions ongoing. 
- **Commercial Strategy**: Collaborating with interventional psychiatry networks to inform launch strategy; COMP360 differentiated by rapid-acting, durable efficacy profile. 

**【CFO Financial Commentary】**
- **2024 Financials**: Net loss of $155.1M; R&D expenses $119M, G&A $59.2M. Cash balance of $165.1M at year-end, plus $140M from January financing. 
- **2025 Guidance**: Net cash use expected between $120M-$145M, providing runway through 2026 data readouts. 

**【Q&A Key Highlights】**
- **Trial Design & Safety**: 005 trial powered for a 5-point MADRS difference; DSMB reviews safety data quarterly with no amendments. Psychological support model standardized to isolate drug effects. 
- **Competitive Landscape**: PTSD market has no new approvals in 20+ years; COMP360's single-dose durability differentiates from chronic treatments. 
- **Regulatory Environment**: FDA engagement on PTSD program expected to accelerate with brexpiprazole AdCom insights. 


CMPS

CMPS fundamentals

Earnings Call

You can ask Aime